Sugi Predict

Sugi Predict / Compounds / SCHEMBL17304013

SCHEMBL17304013

SCHEMBL17304013

Cc1cc(N)c(OC(F)(F)F)cc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ CYP3A4 P08684 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HRH4 Q9H3N8 1/20 0.33
▸ MBOAT4 Q96T53 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ HSP90AA1 P07900 1/20 0.32
▸ HSP90AB1 P08238 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ G6PD P11413 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30640833 1.00 L3MBTL1 (0.42) L3MBTL1POLBCYP3A4TSHRMAPK1
SCHEMBL19927536 0.84 CYP3A4 (0.42) L3MBTL1POLBCYP3A4TSHRMAPK1
SCHEMBL30860858 0.79 POLB (0.39) L3MBTL1POLBCYP3A4TSHRMAPK1
SCHEMBL27228391 0.79 POLB (0.39) L3MBTL1POLBCYP3A4TSHRMAPK1
SCHEMBL31714229 0.79 MBOAT4 (0.38) L3MBTL1POLBCYP3A4TSHRMAPK1
SCHEMBL19643587 0.79 L3MBTL1 (0.39) L3MBTL1POLBMAPTHRH4ALDH1A1
SCHEMBL31533759 0.77 L3MBTL1 (0.43) L3MBTL1POLBCYP3A4MAPK1MAPT
SCHEMBL10261819 0.76 L3MBTL1 (0.60) L3MBTL1POLBCYP3A4TSHRMAPK1
SCHEMBL1701259 0.76 POLB (0.72) L3MBTL1POLBCYP3A4TSHRMAPK1
SCHEMBL31451595 0.76 POLB (0.72) L3MBTL1POLBCYP3A4TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296939-A1 BENZOTHIOPHENE COMPOUND KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2025-09-25 — — US disclosed
US-20250282724-A1 BENZOTRIAZOLE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-09-11 — — US disclosed
US-12378260-B2 Benzotriazole compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-08-05 — — US disclosed
US-20250092064-A1 BENZOTRIAZOLE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-03-20 — — US disclosed
EP-4516792-A1 BENZOTHIOPHENE COMPOUND Kyoto Pharmaceutical Industries, Ltd. (JP) 2025-03-05 — — EP disclosed
EP-4509504-A1 BENZOTRIAZOLE COMPOUND Daiichi Sankyo Company, Limited (JP) 2025-02-19 — — EP disclosed
WO-2023210741-A1 BENZOTRIAZOLE COMPOUND 第一三共株式会社 2023-11-02 — — WO disclosed
WO-2023210740-A1 BENZOTHIOPHENE COMPOUND 第一三共株式会社 2023-11-02 — — WO disclosed
EP-3150592-B1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO LTD (CN) 2023-08-30 — — EP disclosed
EP-3507275-B1 CXCR3 RECEPTOR AGONISTS RECEPTOS LLC (US) 2023-04-26 — — EP disclosed
US-11040954-B1 CXCR3 receptor agonists RECEPTOS LLC (US) 2021-06-22 — — US disclosed
US-20190345133-A1 CXCR3 RECEPTOR AGONISTS RECEPTOS LLC 2019-11-14 — — US disclosed
US-20190345133-A1 CXCR3 RECEPTOR AGONISTS RECEPTOS LLC 2019-11-14 — — US disclosed
EP-3507275-A1 CXCR3 RECEPTOR AGONISTS Celgene International II Sarl (CH) 2019-07-10 — — EP disclosed
US-10023593-B2 ALK kinase inhibitor, and preparation method and uses thereof BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) 2018-07-17 — — US disclosed
WO-2018045246-A1 CXCR3 RECEPTOR AGONISTS CELGENE INTERNATIONAL II SARL (CH) 2018-03-08 — — WO disclosed
WO-2018045246-A1 CXCR3 RECEPTOR AGONISTS CELGENE INTERNATIONAL II SARL (CH) 2018-03-08 — — WO disclosed
US-20170247392-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) 2017-08-31 — — US disclosed
EP-3150592-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF Beijing Pearl Biotechnology Limited Liability Company (CN) 2017-04-05 — — EP disclosed
WO-2015180685-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF 北京浦润奥生物科技有限责任公司 2015-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296939-A1 BENZOTHIOPHENE COMPOUND NFE2L2, KEAP1, BPTF L3MBTL1 3259/4885POLB 3256/4885CYP3A4 2276/4885
US-20170247392-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF ALK, BRAF, ABL1 L3MBTL1 3674/4885POLB 2723/4885CYP3A4 1080/4885
US-10023593-B2 ALK kinase inhibitor, and preparation method and uses thereof ALK, BRAF, ABL1 L3MBTL1 3674/4885POLB 2723/4885CYP3A4 1080/4885
US-11040954-B1 CXCR3 receptor agonists CXCR3, CXCR1, CCR7 L3MBTL1 2670/4885POLB 2573/4885CYP3A4 1911/4885
US-20190345133-A1 CXCR3 RECEPTOR AGONISTS CXCR3, CXCR1, CCR7 L3MBTL1 2670/4885POLB 2573/4885CYP3A4 1911/4885
US-20250092064-A1 BENZOTRIAZOLE COMPOUND NFE2L2, BPTF, KEAP1 L3MBTL1 2615/4885POLB 1565/4885CYP3A4 2097/4885
US-12378260-B2 Benzotriazole compound NFE2L2, BPTF, KEAP1 L3MBTL1 2615/4885POLB 1565/4885CYP3A4 2097/4885
US-20250282724-A1 BENZOTRIAZOLE COMPOUND NFE2L2, BPTF, KEAP1 L3MBTL1 2615/4885POLB 1565/4885CYP3A4 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.